whitepaper
Beyond the lab: cancer research
Our inaugural report is an exploration of the remarkable advancements in cancer research and the field of drug discovery.
List view / Grid view
Research & Development
whitepaper
Application note: Solutions for your protein sample preparation workflow challenges
Researchers often encounter common problems during protein sample preparation which can compromise the quality and quantity of protein obtained. Explore our solutions to these common challenges, including sample handling, storage and preparation method issues.
article
Inflammation discovery offers hope for age-related diseases
Researchers have made a significant breakthrough in the field of ageing research, uncovering a key driver of chronic inflammation that accelerates the ageing process.
news
Launching Revvity: a scientific solutions company powering innovation from discovery to cure
Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure.
article
Light-activated graphene tattoo shows promise in treating heart rhythm disorders
This article outlines the development of the first cardiac implant made from graphene, which is thinner than a single strand of hair yet still functions like a classical pacemaker. It melds softly to the heart to simultaneously sense and treat irregular heartbeats, making it ideal for conforming to soft, dynamic…
whitepaper
Under the microscope: The remit of expertise putting nanomaterials to work
Tom Darlington, Senior Director at nanoComposix, discusses scaling up manufacturing of nanomaterials for regulated applications and the rewards of working on biomedical projects.
news
New class of ribosomal peptide “daptides” discovered by researchers
Researchers from the University of Illinois have identified a new class of ribosomally synthesised and post-translationally modified peptides (RiPPs) named "daptides" that have haemolytic activity.
article
2023 and beyond: revolutionising drug discovery
Drug discovery trends in 2023 will change the way we conduct science and result in entirely new, more efficient, and effective research paradigms. Through increased public-private partnerships, multidisciplinary collaboration and patient engagement in the drug discovery process, we will see new vaccines and therapies getting to the public faster and…
article
Progress towards an RSV vaccine
Despite decades without vaccine development in the respiratory syncytia virus (RSV) space, researchers are now homing in on a potential strategy to protect individuals from this disease. Here, Drug Target Review’s Ria Kakkad spoke with Dr Christy Comeaux, Medical Lead (RSV), Janssen, about the challenges associated with RSV vaccine development and her most promising…
podcasts
Episode 15 – Minimise variability issues in your organoids
Join our experts as they discuss factors causing variability issues in organoids and how to avoid them.
news
CIRM grant $4.8m to fund gene therapy for rare disease
CIRM grant will fund novel gene therapy that aims for single lifelong treatment of Friedreich’s ataxia, a progressive neuromuscular disorder; a second CIRM grant will advance efforts to leverage UC San Diego research on another rare disease
news
SK bioscience collaborates with IVI to support global R&D
SK bioscience and IVI convened in consultative meeting to discuss cooperation for next pandemic and announced KRW3 billion donation to IVI to support advancement of global vaccine R&D
news
The nose-brain pathway: the intranasal administration of drugs to the CNS
Japanese scientists underwent a study exploring trigeminal nerves and how the intranasal administration of the novel glucagon-like peptide-2 can produce antidepressant effects in mice.
news
Altasciences receives accreditation from College of American Pathologists
The College of American Pathologists has given accreditation to Altasciences’ clinical site in Los Angeles, California.
news
Simcere receives clearance to investigate a bi-functional fusion protein drug
The FDA has cleared the Simcere's investigational new drug application for SIM0237, an anti-PD-L1/IL-15 bi-functional fusion protein, for the treatment of adult patients with advanced solid tumours.